压力感受器激活治疗用于射血分数降低的心力衰竭患者
BeAT-HF 试验为多中心前瞻性随机对照研究,408 例 HFrEF 患者按 1:1 随机接受 BAT 联合最佳药物治疗或单纯最佳药物治疗。在反映 FDA 获批使用人群的 D 队列(245 例,随访 6 个月)中,BAT 安全且显著改善生活质量、6 分钟步行距离和 NT-proBNP。
要点
- BAT 在 HFrEF 患者中安全,主要不良神经/心血管或操作相关事件无事件率达 97%。
- BAT 组 6 个月生活质量评分、6 分钟步行距离及 NT-proBNP 均较对照组显著改善。
- D 队列对应 FDA 批准的使用人群,即入组标准加 NT-proBNP <1,600 pg/ml。
核心结论
- BAT 在 HFrEF 患者中安全,并显著改善生活质量、运动能力和 NT-proBNP。
研究设计与样本
- BeAT-HF 为多中心、前瞻性、随机、对照试验,408 例 HFrEF 患者按 1:1 随机分入 BAT 联合最佳药物治疗组或单纯最佳药物治疗组。
- 入组标准包括当前 NYHA III 级或近期有 NYHA III 级病史的 II 级、射血分数 ≤35%、稳定药物治疗 ≥4 周且无心脏再同步治疗 I 类适应证。
主要发现
- D 队列 245 例随访 6 个月(BAT 组 120 例,对照组 125 例),BAT 组生活质量评分降低 Δ=-14.1(95%CI:-19 至 -9;p<0.001)。
- BAT 组 6 分钟步行距离增加 Δ=60 m(95%CI:40 至 80 m;p<0.001)。
- BAT 组 NT-proBNP 降低 Δ=-25%(95%CI:-38% 至 -9%;p=0.004)。
- BAT 组主要不良神经/心血管或操作相关事件无事件率为 97%(95%CI:93% 至 100%;p<0.001)。
临床怎么用
- 对于符合 D 队列标准(含 NT-proBNP <1,600 pg/ml)的 HFrEF 患者,BAT 可作为改善生活质量和运动能力的辅助治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study demonstrated the safety and effectiveness of baroreflex activation therapy (BAT) in patients with heart failure with reduced ejection fraction (HFrEF). OBJECTIVES: The BeAT-HF (Baroreflex Activation Therapy for Heart Failure) trial was a multicenter, prospective, randomized, controlled trial; subjects were randomized 1:1 to receive either BAT plus optimal medical management (BAT group) or optimal medical management alone (control group). METHODS: Four patient cohorts were created from 408 randomized patients with HFrEF using the following enrollment criteria: current New York Heart Association (NYHA) functional class III or functional class II (patients who had a recent history of NYHA functional class III); ejection fraction ≤35%; stable medical management for ≥4 weeks; and no Class I indication for cardiac resynchronization therapy. Effectiveness endpoints were the change from baseline to 6 months in 6-min hall walk distance (6MHW), Minnesota Living with HF Questionnaire quality-of-life (QOL) score, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. The safety endpoint included the major adverse neurological or cardiovascular system or procedure-related event rate (MANCE). RESULTS: Results from, timeline and rationale for, cohorts A, B, and C are presented in detail in the text. Cohort D, which represented the intended use population that reflected the U.S. Food and Drug Administration-approved instructions for use (enrollment criteria plus NT-proBNP <1,600 pg/ml), consisted of 245 patients followed-up for 6 months (120 in the BAT group and 125 in the control group). BAT was safe and significantly improved QOL, 6MHW, and NT-proBNP. In the BAT group versus the control group, QOL score decreased (Δ = -14.1; 95% confidence interval [CI]: -19 to -9; p < 0.001), 6MHW distance increased (Δ = 60 m; 95% CI: 40 to 80 m; p < 0.001), NT-proBNP decreased (Δ = -25%; 95% CI: -38% to -9%; p = 0.004), and the MANCE free rate was 97% (95% CI: 93% to 100%; p < 0.001). CONCLUSIONS: BAT was safe and significantly improved QOL, exercise capacity, and NT-proBNP. (Baroreflex Activation Therapy for Heart Failure [BeAT-HF]; NCT02627196).
引用
- Zile MR, Lindenfeld J, Weaver FA, et al. Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2020. PMID: 32616150. doi:10.1016/j.jacc.2020.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。